- Home
- LVLU vs LYRA Comparison
LVLU vs LYRA Comparison
Compare LVLU & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LVLU
- LYRA
- Stock Information
- Founded
- LVLU 1996
- LYRA 2005
- Country
- LVLU United States
- LYRA United States
- Employees
- LVLU N/A
- LYRA N/A
- Industry
- LVLU Catalog/Specialty Distribution
- LYRA Medical/Dental Instruments
- Sector
- LVLU Consumer Discretionary
- LYRA Health Care
- Exchange
- LVLU Nasdaq
- LYRA Nasdaq
- Market Cap
- LVLU 18.4M
- LYRA 15.0M
- IPO Year
- LVLU 2021
- LYRA 2020
- Fundamental
- Price
- LVLU $4.66
- LYRA $9.01
- Analyst Decision
- LVLU Hold
- LYRA Buy
- Analyst Count
- LVLU 2
- LYRA 2
- Target Price
- LVLU $1.00
- LYRA $16.00
- AVG Volume (30 Days)
- LVLU 782.4K
- LYRA 244.0K
- Earning Date
- LVLU 08-13-2025
- LYRA 08-13-2025
- Dividend Yield
- LVLU N/A
- LYRA N/A
- EPS Growth
- LVLU N/A
- LYRA N/A
- EPS
- LVLU N/A
- LYRA N/A
- Revenue
- LVLU $302,783,000.00
- LYRA $1,185,000.00
- Revenue This Year
- LVLU N/A
- LYRA N/A
- Revenue Next Year
- LVLU $2.53
- LYRA $1,286.17
- P/E Ratio
- LVLU N/A
- LYRA N/A
- Revenue Growth
- LVLU N/A
- LYRA N/A
- 52 Week Low
- LVLU $0.22
- LYRA $3.81
- 52 Week High
- LVLU $5.25
- LYRA $37.50
- Technical
- Relative Strength Index (RSI)
- LVLU 41.76
- LYRA 44.30
- Support Level
- LVLU $3.30
- LYRA $8.69
- Resistance Level
- LVLU $5.43
- LYRA $9.36
- Average True Range (ATR)
- LVLU 1.44
- LYRA 1.07
- MACD
- LVLU -0.13
- LYRA -0.58
- Stochastic Oscillator
- LVLU 26.59
- LYRA 10.11
About LVLU Lulu's Fashion Lounge Holdings Inc.
Lulus Fashion Lounge Holdings Inc is a fashion brand serving Millennial and Gen Z women. Its products include Fall Dresses, Winter Dresses, Sweater Dresses, Short Dresses, Casual Dresses, Wedding Dresses, and Denims, among others. The company generates majority of its revenue from customers based in the United States.
About LYRA Lyra Therapeutics Inc.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.